Literature DB >> 25709097

Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans.

Jose Cortes-Briones1, Patrick D Skosnik2, Daniel Mathalon3, John Cahill2, Brian Pittman4, Ashley Williams5, R Andrew Sewell2, Mohini Ranganathan2, Brian Roach6, Judith Ford3, Deepak Cyril D'Souza2.   

Abstract

Gamma (γ)-band oscillations play a key role in perception, associative learning, and conscious awareness and have been shown to be disrupted by cannabinoids in animal studies. The goal of this study was to determine whether cannabinoids disrupt γ-oscillations in humans and whether these effects relate to their psychosis-relevant behavioral effects. The acute, dose-related effects of Δ-9-tetrahydrocannabinol (Δ(9)-THC) on the auditory steady-state response (ASSR) were studied in humans (n=20) who completed 3 test days during which they received intravenous Δ(9)-THC (placebo, 0.015, and 0.03 mg/kg) in a double-blind, randomized, crossover, and counterbalanced design. Electroencephalography (EEG) was recorded while subjects listened to auditory click trains presented at 20, 30, and 40 Hz. Psychosis-relevant effects were measured with the Positive and Negative Syndrome scale (PANSS). Δ(9)-THC (0.03 mg/kg) reduced intertrial coherence (ITC) in the 40 Hz condition compared with 0.015 mg/kg and placebo. No significant effects were detected for 30 and 20 Hz stimulation. Furthermore, there was a negative correlation between 40 Hz ITC and PANSS subscales and total scores under the influence of Δ(9)-THC. Δ(9)-THC (0.03 mg/kg) reduced evoked power during 40 Hz stimulation at a trend level. Recent users of cannabis showed blunted Δ(9)-THC effects on ITC and evoked power. We show for the first time in humans that cannabinoids disrupt γ-band neural oscillations. Furthermore, there is a relationship between disruption of γ-band neural oscillations and psychosis-relevant phenomena induced by cannabinoids. These findings add to a growing literature suggesting some overlap between the acute effects of cannabinoids and the behavioral and psychophysiological alterations observed in psychotic disorders.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25709097      PMCID: PMC4613601          DOI: 10.1038/npp.2015.53

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  67 in total

1.  Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations.

Authors:  N Hájos; I Katona; S S Naiem; K MacKie; C Ledent; I Mody; T F Freund
Journal:  Eur J Neurosci       Date:  2000-09       Impact factor: 3.386

2.  Canonical correlation analysis applied to remove muscle artifacts from the electroencephalogram.

Authors:  Wim De Clercq; Anneleen Vergult; Bart Vanrumste; Wim Van Paesschen; Sabine Van Huffel
Journal:  IEEE Trans Biomed Eng       Date:  2006-12       Impact factor: 4.538

3.  Molecular composition of the endocannabinoid system at glutamatergic synapses.

Authors:  István Katona; Gabriella M Urbán; Matthew Wallace; Catherine Ledent; Kwang-Mook Jung; Daniele Piomelli; Ken Mackie; Tamás F Freund
Journal:  J Neurosci       Date:  2006-05-24       Impact factor: 6.167

4.  Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients.

Authors:  Gregory A Light; Jung Lung Hsu; Ming H Hsieh; Katrin Meyer-Gomes; Joyce Sprock; Neal R Swerdlow; David L Braff
Journal:  Biol Psychiatry       Date:  2006-08-07       Impact factor: 13.382

5.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

6.  Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex.

Authors:  S M Eggan; D S Melchitzky; S R Sesack; K N Fish; D A Lewis
Journal:  Neuroscience       Date:  2010-06-11       Impact factor: 3.590

7.  Stimulus specificity of phase-locked and non-phase-locked 40 Hz visual responses in human.

Authors:  C Tallon-Baudry; O Bertrand; C Delpuech; J Pernier
Journal:  J Neurosci       Date:  1996-07-01       Impact factor: 6.167

8.  The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories.

Authors:  Michelle Carbuto; R Andrew Sewell; Ashley Williams; Kim Forselius-Bielen; Gabriel Braley; Jacqueline Elander; Brian Pittman; Ashley Schnakenberg; Savita Bhakta; Edward Perry; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2011-08-16       Impact factor: 4.530

Review 9.  GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia.

Authors:  Guillermo Gonzalez-Burgos; David A Lewis
Journal:  Schizophr Bull       Date:  2008-06-26       Impact factor: 9.306

10.  The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning.

Authors:  P D Morrison; V Zois; D A McKeown; T D Lee; D W Holt; J F Powell; S Kapur; R M Murray
Journal:  Psychol Med       Date:  2009-04-01       Impact factor: 7.723

View more
  21 in total

Review 1.  The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Authors:  Britta Hahn
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

2.  Adolescent Δ9-Tetrahydrocannabinol Exposure and Astrocyte-Specific Genetic Vulnerability Converge on Nuclear Factor-κB-Cyclooxygenase-2 Signaling to Impair Memory in Adulthood.

Authors:  Yan Jouroukhin; Xiaolei Zhu; Alexey V Shevelkin; Yuto Hasegawa; Bagrat Abazyan; Atsushi Saito; Jonathan Pevsner; Atsushi Kamiya; Mikhail V Pletnikov
Journal:  Biol Psychiatry       Date:  2018-08-16       Impact factor: 13.382

Review 3.  Different Paths to Core Pathology: The Equifinal Model of the Schizophrenia Syndrome.

Authors:  Isobel W Green; Jill R Glausier
Journal:  Schizophr Bull       Date:  2015-09-20       Impact factor: 9.306

Review 4.  New vistas on cannabis use disorder.

Authors:  Miriam Melis; Roberto Frau; Peter W Kalivas; Sade Spencer; Vivian Chioma; Erica Zamberletti; Tiziana Rubino; Daniela Parolaro
Journal:  Neuropharmacology       Date:  2017-03-31       Impact factor: 5.250

5.  Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC).

Authors:  Anahita Bassir Nia; Maria J Orejarena; Leigh Flynn; Christina Luddy; Deepak Cyril D'Souza; Patrick D Skosnik; Brian Pittman; Mohini Ranganathan
Journal:  Psychopharmacology (Berl)       Date:  2022-04-19       Impact factor: 4.530

6.  Endocannabinoid Signaling Regulates Sleep Stability.

Authors:  Matthew J Pava; Alexandros Makriyannis; David M Lovinger
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

7.  Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans.

Authors:  Patrick D Skosnik; Mihály Hajós; Jose A Cortes-Briones; Chad R Edwards; Brian P Pittman; William E Hoffmann; Andrew R Sewell; Deepak C D'Souza; Mohini Ranganathan
Journal:  Neuropharmacology       Date:  2018-03-28       Impact factor: 5.250

Review 8.  The early identification of psychosis: can lessons be learnt from cardiac stress testing?

Authors:  Swapnil Gupta; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2015-11-14       Impact factor: 4.530

9.  EXTENDED ATTENUATION OF CORTICOSTRIATAL POWER AND COHERENCE AFTER ACUTE EXPOSURE TO VAPOURIZED Δ9 TETRAHYDROCANNABINOL IN RATS.

Authors:  Tapia Foute Nelong; Bryan W Jenkins; Melissa L Perreault; Jibran Y Khokhar
Journal:  Can J Addict       Date:  2019-09

Review 10.  Effects of Cannabis Consumption on Sleep.

Authors:  Alejandra Mondino; Matías Cavelli; Joaquín González; Eric Murillo-Rodriguez; Pablo Torterolo; Atilio Falconi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.